Patients falling below the 25th percentile were categorized as “Low,” those between the 25th and 75th percentiles as “Medium,” and those above the 75th percentile as “High.” Results revealed a heterogeneous pattern of RAG1 and RAG2 expression in gliomas, with a strong bias toward high and mid-level expression of both genes (Figure 1A). The gene discussed is RAG1; the disease is central nervous system cancer.